Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. [electronic resource]
Producer: 20140121Description: 813-8 p. digitalISSN:- 1536-4828
- Aged
- Aged, 80 and over
- Anemia -- chemically induced
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Cytokines -- blood
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Etanercept
- Fatigue -- chemically induced
- Female
- Humans
- Immunoglobulin G -- administration & dosage
- Interferon-gamma -- blood
- Interleukin-10 -- blood
- Interleukin-1beta -- blood
- Interleukin-6 -- blood
- Male
- Middle Aged
- Nausea -- chemically induced
- Pancreatic Neoplasms -- drug therapy
- Receptors, Tumor Necrosis Factor -- administration & dosage
- Reverse Transcriptase Polymerase Chain Reaction
- Signal Transduction -- drug effects
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- blood
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.